Fobossp. z o.o.
Research and experimental development in natural sciences and engineering
Overview
Financials
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 1 of 2 financial statements was filed late (for 2024, 461 days late).
- 2025not filed
- 202419/10/2026
- 202329/06/2024
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.
Results vs industry
Industry
Authorized Representatives
Manner of representation
The following are authorised to sign and make declarations on behalf of the company: 1. in the case of a one-person management board, the sole member of the management board acting independently; 2. in the case of a multi-member management board, the company shall be represented jointly, provided that, if a Vice-President of the Management Board is appointed, the company shall be represented by the Vice-President of the Management Board together with another member of the management board.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Michalina Reischage 58 | 93 | $1,256.08 | 44.2857% |
Piotr Adam Reischage 60 | 103 | $1,391.14 | 49.0476% |
Others | 14 | $189.09 | 6.6667% |
Piotr Adam Reisch and Michalina Reisch hold a combined 93.3% – the ownership structure indicates family control.
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2024-09-01.
18 1090 0088 0000 0001 5287 5089- 55 1090 0088 0000 0001 5287 4617
- 49 1090 0088 0000 0001 5287 5016
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 26, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Pomorska Specjalna Strefa Ekonomiczna sp. z o.o. | |
| Feb 1, 2023 | Aid for SME access to finance — aid for start-ups | –– | Dyrektor Narodowego Centrum Badań i Rozwoju |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Novo Nordisk Pharmasp. z o.o. | $126,524,177.00 | novonordisk.pl | ||
| GenomedS.A. | $7,373,750.46 | genomed.pl | ||
| Agencja Rynku EnergiiS.A. | $2,676,821.15 | are.waw.pl | ||
| Fluence Technologysp. z o.o. | $2,486,673.06 | fluence.pl | ||
| DR Koziejsp. z o.o. + limited partnership | $770,078.78 | drkoziej.com | ||
| FamicordtxS.A. | $589,673.84 | famicordtx.com | ||
| Care Access Polskasp. z o.o. | $305,248.06 | careaccess.pl | ||
| ETG Zamośćsp. z o.o. | $260,151.02 | etg-network.com | ||
| Codeit4us Rndsp. z o.o. | $152,435.96 | codeit4us.com | ||
| Bio2materialssp. z o.o. | $14,121.59 | bio2materials.com |
FAQ
Last updated: 2026-10-19